This Phase I clinical trial (NCT03051477) evaluates the safety, toxicity, and maximum tolerated dose (MTD) of Helixor® M (mistletoe extract) in 21 patients with advanced solid tumors who have not responded well to first-line therapies. The study consists of a dose escalation phase to assess safety and an expansion phase
